Berkeley, CA (PRWEB) December 19, 2012
Now in its tenth year as an online urology-medical oncology publisher, Digital Science Press, Inc. (DSP) -- UroToday.com is expanding key prostate cancer content with two new sections: immunotherapy treatment for men with metastatic castration-resistant prostate cancer; and advances in metastatic castrate-resistant prostate cancer (mCRPC) treatments for urology and oncology nurses.
“Prostate cancer is the most highly read content on the UroToday website,” says Gina Carithers, publisher, DSP. “For our worldwide readership, the disease has many aspects from screening to diagnosis to treatment -- some developing and others controversial. For example, we will continue to follow the PSA controversy and report how the evidence continues to evolve regarding the impact of PSA screening on overall survival.” UroToday is also doing more multi-media lectures on the development of new therapies and treatments that enable the urologists and medical oncologists to more effectively treat the metastatic castration-resistant prostate cancer patient.
The web platform for UroToday been upgraded to handle the increase in readership, provides easier navigation, a powerful search using Google and personalized access to the recently posted content by disease topic through daily or weekly UroAlerts. “We made an editorial decision earlier this year to focus on the “art of urology.” At conception, UroToday has reported evidence-based medicine (the science of urology); however, we are seeing a fundamental shift within many urology practices to also emphasize quality of life therapies and resources, more towards what we call the art of urology.”
Case in point, the UroToday mini-lecture series on treatments for advanced prostate cancer has now posted two lectures by medical oncologist Chuck Ryan, MD, UC
Copyright©2012 Vocus, Inc.
All rights reserved